Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYHX1901 tablets in non-segmental vitiligo (Phase III, randomized, double-blind, placebo-controlled)
CTR20260391Phase 3Active
- Sponsor
- CSPC Ouyi Pharmaceutical
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Vitiligo comparing SYHX1901 with Placebo (2 arms). Primary endpoint: Proportion of participants achieving F-VASI75 at Week 52. Started Feb 2026; status: active.
02
Drugs
SYHX-1901
03
Conditions
Vitiligo
Beyond the preview
Go deeper on CTR20260391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260391.